Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors

BACKGROUND: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine kinase inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients harboring multiple ALK fusions, including double or triple A...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qi, Zhang, Yuanyuan, Wang, Yongsheng, Desai, Aakash, Tan, Sihan, Huang, Qin, Pu, Xin, Tian, Panwen, Li, Yalun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579835/
https://www.ncbi.nlm.nih.gov/pubmed/37854161
http://dx.doi.org/10.21037/tlcr-23-484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579835/
https://www.ncbi.nlm.nih.gov/pubmed/37854161
http://dx.doi.org/10.21037/tlcr-23-484

Ejemplares similares